Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity
Year: 2017
Type: article
Abstract: Several kinase inhibitors that target aberrant signaling pathways in tumor cells have been deployed in cancer therapy. However, their impact on the tumor immune microenvironment remains poorly understood. The tyrosine kinase inhibitor cabozantinib showed striking responses in cancer clinical trial patients across several malignancies. Here, we show that cabozantinib rapidly eradicates invasive, poorly differentiated PTEN/p53-deficient murine prostate cancer. This was associated with enhanced release of neutrophil chemotactic factors from tumor cells, including CXCL12 and HMGB1, resulting in robust infiltration of neutrophils into the tumor. Critically, cabozantinib-induced tumor clearance in mice was abolished by antibody-mediated granulocyte depletion or HMGB1 neutralization or blockade of neutrophil chemotaxis with the CXCR4 inhibitor plerixafor. Collectively, these data demonstrate that cabozantinib triggers a neutrophil-mediated anticancer innate immune response, resulting in tumor clearance. Significance: This study is the first to demonstrate that a tyrosine kinase inhibitor can activate neutrophil-mediated antitumor innate immunity, resulting in invasive cancer clearance. Cancer Discov; 7(7); 750–65. ©2017 AACR. This article is highlighted in the In This Issue feature, p. 653
Source: Cancer Discovery
Authors: Akash Patnaik, Kenneth D. Swanson, Eva Csizmadia, Aniruddh Solanki, Natalie Landon-Brace, Marina P. Gehring, Katja Helenius, Brian M. Olson, Athalia R. Pyzer, Lily C. Wang, Olivier Elemento, Jesse Novak, Thomas B. Thornley, John M. Asara, Laleh Montaser, Joshua J. Timmons, Todd M. Morgan, Yugang Wang, Elena Levantini, John G. Clohessy, Kathleen Kelly, Pier Paolo Pandolfi, Jacalyn M. Rosenblatt, David E. Avigan, Huihui Ye, Jeffrey M. Karp, Sabina Signoretti, Steven P. Balk, Lewis C. Cantley
Institutions: Beth Israel Deaconess Medical Center, Harvard University, University of Chicago, Dana-Farber/Harvard Cancer Center, University of Chicago Medicine Comprehensive Cancer Center, Brigham and Women's Hospital, Harvard Stem Cell Institute, Pontifícia Universidade Católica do Rio Grande do Sul, Koch Institute for Integrative Cancer Research At MIT, Massachusetts Institute of Technology, Cornell University, Weill Cornell Medicine, University of Michigan, National Research Council, National Cancer Institute
Language: English
Topic: Immune cells in cancer
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2592811353